Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Home Letters Funds Account

1 Main Capital's investment thesis on DIAMEDICA THERAPEUTICS INC ($DMAC) — Q2 2026 | Buyside Digest

All Pitches

View Letter Analysis

$DMACNASDAQDIAMEDICA THERAPEUTICS INC

BULL

1 Main Capital—DMAC

Fund Letter

Q2 2026

Published July 31, 2026

View Fund Profile

$6.73USD

-0.3% vs last month

$7.44Pitched

-9.5% since pitch

Market Cap$362.6M

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Technical Chart

From the Fund Letter

The Fund holds an opportunistic position in DiaMedica Therapeutics (DMAC), a clinical-stage biotechnology company that has developed DM199, a recombinant (synthetic)...

— Yaron Naymark

BSD Research Exclusive

Unlock Full Institutional Investment Theses

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

SUBSCRIBE TO BSD RESEARCH ($55/MO)Compare All Plans

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

What other investors think about $DMAC, and what else 1 Main Capital is buying.

Other pitches on $DMAC

Other investors who've written on DIAMEDICA THERAPEUTICS INC

1 Main CapitalBULL

Pitched Jul 31, 2026

The Fund holds an opportunistic position in DiaMedica Therapeutics (DMAC), a clinical-stage biotechnology company that has developed DM199, a recombinant (synthetic) form of the natural

View all $DMAC pitches →